Plaintiffs Seek Consolidation of Defective Mesh Claims Against Boston Scientific

Last week, the U.S. Judicial Panel on Multidistrict Litigation (JPML) met in Miami.  Among the issues set for hearing were requests to consolidate pending Federal Court cases alleging product defect claims due to transvaginal surgical mesh products against American Medical Systems, Ethicon (Johnson & Johnson) and Boston Scientific.  I have already filed one of these cases against Boston Scientific and am investigating several others.  So, naturally I am very interested in the decision as to where these cases will ultimately be consolidated.

As for the Boston Scientific cases, it is likely that they will be consolidated either before a Federal Judge in West Virginia (as generally sought by plaintiffs' counsel) or a Federal Judge in Oklahoma (as requested by Boston Scientific).  I believe the Federal Court in West Virginia is the best choice.  That Court is already handling similar claims against another mesh manufacturer, C.R. Bard, Inc.. As a result, that Court is familiar with these mesh products in general  as well as many of the medical issues.

The injuries suffered by women who have had these products implanted are very serious and debilitating.  These injuries include serious infections, erosion of the mesh into the tissue, urinary problems, injury to nearby organs, inflammation and severe pain.  Often, additional surgery is necessary to try and correct some of the damage.  In July 2011, the FDA issued a safety update detailing the dangers of transvaginal mesh products.  An article last year on MSNBC also detailed the troubling history of how this product was placed on the market and the tremendous injuries which may result from its use.

Actos Update - MDL Panel Consolidates Cases

The Federal Judicial Panel on Multidistrict Litigation has issued its Order consolidating all pending Actos cases in Federal Court. The cases have been consolidated before U.S. District Judge Rebecca Doherty in the U.S. District Court for the Western District of Louisiana. This means that Judge Doherty will preside over all the pretrial proceedings in these cases. Bloomberg has a good article concerning this decision and its impact on Actos litigation against Takeda Pharmaceutical.

I have written previously on the issues surrounding Actos:

  1. Takeda May Face Thousands of Lawsuits over Actos - overview of the potential claims facing Takeda due to its diabetes drug.
  2. Type 2 Diabetes, Actos, and Bladder Cancer - the use of Actos to treat diabetes.

This litigation is only in its early stages. I expect that the court will face a huge number of claims to manage.

The purpose of the multidistrict litigation (MDL) process is to consolidate cases before one court that can handle the various discovery and pretrial proceedings. The idea is that having one court handle the various pretrial issues will conserve resources, save costs, and prevent numerous courts issuing rulings that may be inconsistent. Cases are returned back to the Federal Court where they were originally filed for the trial.